KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a decrease of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, the days-to-cover ratio is currently 19.3 days.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Finally, JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $23.80.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were bought at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now directly owns 4,986,480 shares in the company, valued at $43,681,564.80. This trade represents a 0.88 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now owns 274,596 shares in the company, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 236,055 shares of company stock worth $2,162,146 and have sold 18,043 shares worth $176,758. 10.50% of the stock is currently owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Aquatic Capital Management LLC bought a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $44,000. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc raised its stake in shares of KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares in the last quarter. Finally, Martin Worley Group acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at $86,000.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $10.71 on Thursday. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The firm has a fifty day moving average price of $8.80 and a two-hundred day moving average price of $10.43. The company has a market cap of $529.29 million, a PE ratio of -2.94 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. Analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).